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Parathyroid Tumor Biology in Familial Multiple Endocrine 
Neoplasia Type 1: A Model for Cancer Development 
Maria Luisa Brandi* 
Familial multiple endocrine neoplasia type I (FMEN 1) is an autosomal dominant disorder 
characterized by tumors of the parathyroid glands, pancreatic islets, and anterior pituitaiy. 
Hyperplasia appears to be the typical histopathological lesion in FMEN 1 endocrine tumors. A 
circulating mitogen related to basic fibroblast growth factor was active on proliferation of clonal 
bovine and human parathyroid endothelial cells. Moreover, the FMEN 1 mitogen modulated 
differentiation of human parathyroid endothelial cell in vitro. All these facts suggested that an 
extrinsic factor was active on parathyroid endothelial cell growth and differentiation. The FMEN I 
gene maps to chromosome I Iql3, and allelic loss in this region has been shown in FMEN 1 
parathyroid and pancreatic islet tumors and rarely in anterior pituitary tumors. Together these 
results support the theory that FMEN 1 parathyroid clonal lesions can develop in the context of 
generalized hyperplasia. Similarly, in uremic hyperparathyroidism, where parathyroid hyperplasia 
is thought to be the primary lesion, loss of constitutional heterozygosity for chromosome II markers 
coexists in parathyroid tissue with a polyclonal pattern. Future efforts of scientists working on this 
genetic disorder will focus on the cloning of the FMEN 1 gene and the development of a suitable 
bioassay system to study its function. (Henry Ford Hosp Med J 1992;40:181-5) 
During the past seven years, we have been working on the cellular biology of parathyroid tissue, with a particular in-
terest in "hyperplastic" parathyroid tumors of patients affected 
by familial multiple endocrine neoplasia type 1 (FMEN 1), 
a disorder in which subjects develop not only hyperparathy-
roidism but also tumors of the pituitary glands and the endocrine 
pancreas (1). 
This model became important for understanding the signifi-
cant events in parathyroid tumor development. We review the 
progress of our laboratory and that of others in defining the mo-
lecular abnormalities of FMEN 1 endocrine tumors. 
Mechanisms Underlying Tiimor 
Development in FMEN 1 Syndrome 
DNA restriction fragment length polymorphism studies of 
lymphocyte DNA have linked the germline genetic abnormality 
for FMEN 1 to the long arm of chromosome 11 region ql3 (2). 
It was initially proposed (2) that the mechanism of the tumor-
igenesis via the chromosome 11 in FMEN 1 tumors might be 
similar to that of retinoblastoma (3) and of several other herita-
ble cancers (4-6), where loss of a recessive tumor suppressor 
function is thought to play the initial role in tumor development. 
This theory is based on the "two hit" hypothesis of carcinogene-
sis developed by Knudson (3) for formation of retinoblasto-
ma. In the familial form of retinoblastoma, the first "hit" is a 
germline genetic defect which is assumed to be phenotypically 
silent as long as the normal allele is functionally intact. Altema-
tively, the first hit in target tissues might not be silent but may 
contribute to the generalized hyperplasia that precedes tumor 
development in familial cancers. The stimulus for this polyclo-
nal hyperplastic growth may refiect an intrinsic abnormality of 
the target cell or else an extrinsic stimulus for the entire cell pop-
ulation. The second "hit" becomes manifest in occasional cells 
via loss of the remaining normal gene allele. Subsequent clonal 
tumor growth ensues from the cells that have suffered these two 
hits. Tbis process is usually multifocal and each tumor comes 
from a different cell clone (7). This multiplicity refiects the ini-
tial genetic abnormality of the hyperplastic cell population. 
Pathology of FMEN 1 l\imors 
The tumors in FMEN 1 syndrome tend to be multiple in the 
involved organ. Moreover, even though FMEN 1 syndrome has 
a generalized hyperplastic phase (8), a complete spectmm of hy-
perplasia, microadenomas, adenomas, carcinomas, and carci-
noid changes have been found on pathological examination. In 
FMEN 1 patients the major histologic abnormality is parathy-
roid hyperplasia. Gland size is markedly irregular in parathyroid 
hyperplasia and sometimes one or even two of the glands can be 
of normal weight. The nature of parathyroid lesions is usually 
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Fig I—Primary cultures of FMEN I glucagonoma tissue. Cells 
were cultured for seven (A) and 30(B) days in Coon's modified 
Ham's F12 medium containing 10% FCS. Original magnifica-
tion X250. 
that of chief cell hyperplasia. Nevertheless, a number of FMEN 
1 patients have been reported with one or more parathyroid ade-
nomas. However, proof of long-term cure of hyperparathy-
roidism following removal of a single parathyroid adenoma is 
rarely found in FMEN 1. These observations are suggestive of 
the coexistence of both forms of parathyroid disease, adenoma 
and hyperplasia, in the same genetic setting. 
Similar to the lesions in the parathyroid glands, the abnormal-
ities in the islet cells in the FMEN 1 syndrome consist of diffuse 
hyperplasia, affecting either a single type of cell or two or more 
different types. The endocrine pancreas in FMEN 1 syndrome 
displays single or multiple benign or malignant islet cell neo-
plasms. 
In patients with the FMEN 1 syndrome, the anterior pituitary 
lesion is commonly an adenoma, generally solitary. However, 
multiple pituitary tumors with increased plasma prolactin and 
growth hormone concentrations have been reported. Histologi-
cally, pituitary lesions can consist of chromophobe, eosinophil, 
basophil, or mixed cell types. 
Adrenal abnormalities in FMEN 1 syndrome generally con-
sist of diffuse or nodular hyperplasia. Occasionally there may be 
a cortical adenoma or even carcinoma. In only a few cases does 
the clinical history indicate that the tumors have functioned. 
The pattem of thyroid involvement is inconsistent. Thyroid 
adenoma, colloid goiter, thyroid carcinoma, and thyrotoxicosis 
have been reported. 
Primary carcinoids of the bronchus and thymus do not differ 
from sporadic tumors, while carcinoids of the gastric mucosa 
are characterized by multicentricity. Indeed, hyperplasia of ar-
gyrophil endocrine cells is regularly noted in the hypertrophic 
oxyntic mucosa of Zollinger-Ellison patients, a finding gener-
ally attributed to the trophic action of gastrin on the main type of 
endocrine cell located in this mucosa, the so-called enterochro-
maffin-like (ECL) cell (9). In addition to ECL hyperplasia, tu-
mors of this cell type having the morphological appearance of 
carcinoids arise frequendy in patients with gastrinoma in the 
setting of FMEN 1 syndrome (10). These findings have been in-
terpreted as an effect of gastrin upon genetically altered ECL 
cells to promote tumor growth. 
Tumors of FMEN 1 patients have been extensively character-
ized by morphologists; however, only limited data are available 
on preneoplastic lesions developing in man. Transgenic mice 
bearing tumors of the anterior pituitary and pancreas have been 
proposed as useful tools to improve our understanding of herita-
ble endocrine tumor disease in human pathology (11). The mor-
phological steps of tumor development in these animals were 
analyzed and preneoplastic features were described. Hyperpla-
sia together with dysplasia and dysplasia without hyperplasia 
were the lesions preceding tumor formation in these transgenic 
animals (11). 
Cell Biology of FMEN 1 Tiimors 
Studies with cell cultures have begun to clarify some of the 
mechanisms which underlie growth dysfunction in the parathy-
roid tissue. This progress has been mainly due to the develop-
ment of rat epithelial (12) and bovine endothelial (13) clonal cell 
lines from parathyroid tissue. The use of such in vitro models 
made it possible to demonstrate that a mitogen closely related to 
basic fibroblast growth factor (bFGF) is circulating at high con-
centrations in FMEN 1 syndrome (14,15). Bovine parathyroid 
endothelial cells represented a target for this growth factor, sug-
gesting the possibility that a bFGF-like factor may act systemi-
cally on parathyroid angiogenesis and, therefore, indirectly on 
proliferation of the epithelial component of parathyroid tissue. 
We have also shown that bovine parathyroid endothelial cells 
release factor(s) able to stimulate proliferation of rat parathyroid 
epithelial cells and vice versa (16). These observations pointed 
to the importance of considering the stromal cells of the endo-
crine tissue as active components of the metabolic activities of 
the glands. Moreover, these findings suggested the possibility 
that a soluble endothelial cell growth factor may play a critical 
role in the growth of the parathyroid tissue in FMEN 1, support-
ing the hypothesis of a generalized polyclonal proliferation of 
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the glands. However, the main limitation of our studies was the 
lack of human cell models to evaluate the mechanisms -which 
underlie cell proliferation and cell to cell interactions in the en-
docrine organs involved in the FMEN 1 syndrome. We have, 
therefore, developed both primary cultures as well as clonal cell 
lines from FMEN 1 endocrine tumors. 
Primary cultures are an ideal system for in vitro studies on 
cell differentiation, refiecting well the in vivo tissue heterogene-
ity. However, this cellular heterogeneity is also the main cause 
of cell culture variability observed in multiple experiments. In 
fact, depending on the composition of the tissue of origin (ratio 
of stromal/epithelial components, etc.) and also on the tissue 
manipulation (enzyme digestion, adhesion properties, growth 
capability, etc.), great heterogeneity exists between one tissue 
preparation and the other. Moreover, primary cultures are des-
tined to be overgrown by fibroblast-like cells (Fig 1 [A and B]) 
and therefore the epithelial component has a limited life span. 
Even though all ofthese limitations must be considered, prelim-
inary studies using primary cultures of FMEN 1 endocrine tis-
sue appear promising. Parathyroid cells obtained from FMEN 1 
parathyroid tissue and cultured for seven days in the presence of 
10% fetal calf serum (FCS) exhibited an epithelial morphology 
with a tendency to not proliferate (Fig 2A). The replacement of 
FCS with 10% MEN 1 plasma induced cell proliferation and 
spreading (Fig 2B). We have also developed primary cultures 
from pancreatic islet tumors of patients with FMEN 1 syn-
drome. In our experience pancreatic endocrine cells adhere to 
the plastic dishes (Fig 1 A) or could be maintained as suspension 
cultures (Fig 3). Primary cultures of FMEN 1 pituitary tissue 
formed clusters remini.scent of the pituitary follicular cells (Fig 
4). 
Recentiy, we have cloned an endothelial (HPE) cell line from 
FMEN 1 parathyroid tissue. The fact that the bovine parathyroid 
endothelium was the target of the mitogenic effect of the bFGF-
like mitogen (14,15) prompted further tests on the newly devel-
oped human cell line. Preliminary results showed clearly not 
only a potent proliferative effect of FMEN 1 plasma on HPE cell 
proliferation, but also an induction of endothelial differentiative 
features required in angiogenesis. The growth of new capillar-
ies, whether in development, wound healing, tumor angiogene-
sis, arthritis, or diabetes, requires lumen formation and migra-
tion of endothelial cells. Confiuent HPE cells cultured in the 
presence of 10% FMEN 1 plasma exhibited a pecuhar "ring" 
shape (Fig 5). This morphological correlate may indicate a role 
ofthe FMEN 1 plasma in the lumen formation via vacuolization 
ofthe endothelial cells or else by cylindrical curvature of the cell 
membrane. When HPE cells were incubated in medium contain-
ing FCS they either remained quiescent or moved slowly. In re-
sponse to different concentrations of FMEN 1 plasma, the rate 
of cell migration, measured as the surface of the tracks made by 
the cells as they migrated across gold-coated coverslips, in-
creased proportionately. 
Genetics of FMEN 1 Tumors 
The mapping of the FMEN 1 gene to chromosome 11 and the 
implication of the inactivation of negative modulation in the 
Fig 2—Primary cultures of FMEN I parathyroid tissue. Cells 
were cultured for seven days in Coon's modified Ham's F12 me-
dium containing 10% FCS (A) and 10% FMEN 1 plasma (B). 
Original magnification X250. 
pancreatic growth disturbance in FMEN 1 (2) prompted further 
studies on loss of constitutional heterozygosity in FMEN 1 en-
docrine tumors. 
Loss of DNA alleles from one copy of the long arm of chro-
mosome 11 region q 13 has been found in both sporadic and 
FMEN 1 associated tumors (17-20). These results are in agree-
ment with the two-mutational model. In sporadic tumors the 
loss of constitutional heterozygosity is indirect evidence of 
monoclonahty. However, in familial hyperplasia such losses do 
not necessarily refiect a monoclonal composition of the tumor. 
Since these losses serve to eliminate the wild type allele at the 
disease locus, polyclonal and monoclonal tumors may give sim-
ilar pattems of allele losses for chromosome 11 markers. Inter-
estingly, allelic losses specific to chromosome 11 are typical of 
the larger FMEN 1-associated parathyroid lesions (17), suggest-
ing that clonal outgrowth might arise in the context of general-
ized hyperplasia in FMEN 1 parathyroid tissue. In order to better 
understand the relationships between clonal lesions and hyper-
plasia in FMEN 1 parathyroid tumors, we have chosen the 
model of uremic hyperparathyroidism, believed to be hyper-
plastic in origin. We found loss of constitutional heterozygosity 
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Fig 3—Primary cultures of FMEN I insulinoma. Cells were cul-
tured in Coon's modified Ham's F12 medium containing 10% 
FCS. Several cells grew in suspension. Small clusters of adher-
ent cells (arrows] as well as "ring" structures (arrowheads) are 
represented. Original magnification X250. 
Fig 5—Clonal HPE cells maintained in culture for 20 days in 
Coon's modified Ham's FI2 containing 10% FMEN 1 plasma. 
Cells exhibited a typical "ring" shape. Original magnification 
X400. 
Fig 4—Primary cultures of FMEN I prolactinoma. Cells were 
cultured in Coon's modified Ham's F12 medium containing 
10% FCS. Cells formed thick clusters (arrowhead and inset) re-
sembling the follicle-like structures described in primary cul-
tures of bovine pituitary cells. Original magnification X250 and 
X400 (inset). 
for chromosome 11 markers in two of nine glands from five 
uremic patients (21). Interestingly, the two glands with allelic 
losses were significantly greater in mass than those without loss, 
supporting the dieory that parathyroid adenoma can develop 
through overgrowth by a monoclonal tumor in the context of 
generalized hyperplasia. Parathyroid lesions have represented a 
rich opportunity to study molecular changes that occur during 
tumor development. However, the lack of correlation between 
standard histopathology (hyperplasia versus adenoma) and mo-
lecular biology (polyclonal versus monoclonal lesions) studies 
makes it desirable to prepare DNA from microscopic sections of 
tumors, where contiguous sections would be analyzed by histo-
pathology. 
Loss of constitutional heterozygosity has been found also in 
FMEN 1 pancreatic islet cell hyperplasia and in insulinomas 
(2,22). In contrast to parathyroid tumors, many sporadic pancre-
atic islet neoplasms, even when malignant, do not develop 
through homozygous inactivation of the FMEN 1 gene (22). 
The FMEN 1 pituitary lesions are most commonly prolacti-
nomas, a tumor which is only rarely managed by surgical inter-
vention. Therefore, studies of loss of heterozygosity in pituitary 
tumors have been comprised mainly of sporadic pituitary tu-
mors (19). The observation of relatively few allelic losses on 
chromosome 11 in FMEN 1 or sporadic pituitary adenomas sug-
gested that the recessive nature of the germline defect proposed 
for FMEN 1 parathyroid and pancreatic tissues might not be op-
erative in pituitary tumors. 
Finally, FMEN 1 bronchial carcinoid (22), FMEN 1 benign 
adrenal enlargements, and sporadic adrenocortical adenomas 
showed retained genotypes for markers fianking the FMEN 1 re-
gion. 
An altemative explanation for the low incidence for reduction 
of homozygosity in a number of FMEN 1 endocrine tumors 
should be given serious consideration. The two allelic hit theory 
of Knudson (3) might not be operative in these tumors. How-
ever, it is also conceivable that failure to detect reduction of ho-
mozygosity might be due to a mechanism of inactivation of the 
normal allele function that does not involve the loss of a large 
segment of chromosome 11 (i.e., point mutations). Altema-
tively, subsequent genetic events necessary for frank neoplasm 
formation may involve not the opposite normal allele but other 
genetic loci, as suggested in Wilm's tumor (23,24). 
Cytogenetics of FMEN 1 l\imors 
One important line of evidence in support of a genetic origin 
for cancer is the frequent finding of chromosomal abnormalities 
in patients with specific types of tumor. Perhaps the best charac-
terized of these are deletions involving the chromosome region 
13ql4, which are found in tumor tissue of 5% of cases of reti-
noblastoma with normal constitutional karyotypes. Initially, 
karyotype analysis in FMEN 1 patients resulted in an inconsis-
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tent pattem of chromosomal instability in family members with 
the FMEN 1 syndrome (25). Recentiy, analysis of cultured lym-
phocytes and fibroblasts of FMEN 1 patients showed a number 
of chromosome abnormalities with no rearrangements involv-
ing chromosome 11 (26). Similarly, primary cultures of FMEN 
1 pancreatic tumors revealed a number of chromosome abnor-
malities with .several double minute chromosomes of variable 
size and no specific involvement of chromosome 11 (27). 
Prospects 
Cleariy, elucidation ofthe genetic events that underlie the de-
velopment of tumors in FMEN 1 will teach much about the 
range of molecular changes that can contribute to the early 
stages of human cancer. Cytogenetic, cellular, and molecular bi-
ology studies of FMEN 1 tumors will contribute to this under-
standing. The immediate goal of several laboratories is the clon-
ing of the FMEN 1 gene. However, a biologic assay for the 
FMEN 1 gene function would be the ultimate proof of its sup-
pressor nature, similariy to what developed for the retinoblas-
toma gene (28). This will allow introduction of the gene into 
cultured tumor cells that contain inactivated endogenous FMEN 
1 genes. Therefore, the development of an assay system for the 
FMEN 1 gene function remains an important goal. 
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